Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04314011
Recruitment Status : Not yet recruiting
First Posted : March 18, 2020
Last Update Posted : March 18, 2020
Sponsor:
Collaborator:
Xuanwu Hospital, Beijing
Information provided by (Responsible Party):
Shanghai East Hospital

Brief Summary:

The purpose of this clinical study is to answer the questions:

  1. Is the proposed intervention safe?
  2. Is the proposed intervention effective in improving the health of subjects with aging frailty?

Condition or disease Intervention/treatment Phase
Aging Frailty Biological: Human umbilical cord mesenchymal stem cells(HUC-MSCs) Biological: Placebo Phase 1 Phase 2

Detailed Description:

Aging frailty is a clinical syndrome, characterized by a decrease of homeostatic reserves and enhanced vulnerability to endogenous or exogenous stressors, exposing individuals to an increased risk of adverse health-related outcomes. The human umbilical cord (HUC) is a promising source of mesenchymal stem cells (MSCs), compared to embryonic stem cells, HUC-MSCs are noncontroversial with a painless collection procedure and faster self-renewal properties. HUC-MSCs can differentiate into the different germ layers and modulate immune responses. One possible mechanism for the onset and development of aging frailty is the depletion of stem cells. Hence, intravenous infusion of HUC-MSCs is attractive therapy against aging frailty.

This is a randomized, multicenter,double-blind, placebo-controlled clinical trial. The participants from two centers (n = 30) will be randomly distributed into two groups. The HUC-MSCs Group (n = 15) will receive intravenous infusion of mesenchymal stem cells (80 Million) twice over a month (30 days interval), the Control Group (n = 15) will receive the same protocolized intervention with normal saline. Follow-up duration is 6 months after first intervention. The reported serious adverse events(SAEs)will be observed within one month post infusion. The short-item from health survey(SF-36), EuroQol five dimensions questionnaire (EQ-5D) and Fried phenotype scale will be evaluated. Short physical performance battery (SPPB) and plasm biomarkers will be assessed.The assessments will be performed at baseline, 3 months and 6 months.

The intent of this study is to explore domains of efficacy of HUC-MSCs through the reduction of signs and symptoms of aging frailty and to evaluate the safety of HUC-MSCs in subjects with aging frailty.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty
Estimated Study Start Date : April 1, 2020
Estimated Primary Completion Date : April 1, 2021
Estimated Study Completion Date : April 1, 2021

Arm Intervention/treatment
Experimental: HUC-MSCs Group
Human umbilical cord mesenchymal stem cells (80 Million cells/200ml): delivered via peripheral intravenous infusion.
Biological: Human umbilical cord mesenchymal stem cells(HUC-MSCs)
Human umbilical cord mesenchymal stem cells(HUC-MSCs)

Placebo Comparator: Control Group
Placebo:normal saline(200ml) delivered via peripheral intravenous infusion.
Biological: Placebo
Placebo




Primary Outcome Measures :
  1. Safety of HUC-MSCs infusion [ Time Frame: Within one month post infusion ]

    Safety were assessed by incidence of reported serious adverse events (SAEs) within one month after infusion. An SAE is defined as any untoward medical occurrence that:

    1. Results in death
    2. Is life-threatening (stroke or non-fatal pulmonary embolism, etc.)
    3. Requires inpatients hospitalization or prolongation of hospitalization
    4. Results in clinically significant abnormal laboratory test results or abnormal vital signs, based on clinical judgment.


Secondary Outcome Measures :
  1. Difference in rate of decline of Frailty [ Time Frame: Baseline, 3 month and 6 months post infusion ]

    Difference in rate of decline of Frailty assessed using Fried phenotype scale:

    1. Slowing of Mobility (assessed via a 4-meter gait speed test; Timed up and go (TUG) test and Short Physical Performance Battery (SPPB) assessment)
    2. Weight Loss (assessed via weighing scale)
    3. Reduced Activity (assessed via Minnesota Leisure Time Activities (MLTA) questionnaire)
    4. Diminished handgrip strength (assessed via dynamometer)
    5. Exhaustion (assessed by two items from the Center for Epidemiological Studies-Depression, CES-D):" I felt that everything I did was an effort? and I could not get going."

  2. Difference in subject quality of life assessments [ Time Frame: Baseline, month 3 and month 6 post infusion ]
    Health-related quality of life will be assessed with 3 subscales of Short-Form 36 Health Survey (SF-36), including physical functioning scale, mental health index and general health perception scale; the health status including Health State Index (HSI) and respondent's self-rated health on a vertical scale will be accessed via EuroQol 5-Dimension (ED-5D).

  3. Changes in the pro-inflammatory cytokines of blood sample between the HUC-MSC and placebo cohorts [ Time Frame: Baseline, month 3 and month 6 post infusion ]
    Enzyme-linked immunosorbent assay will be used to identify the serum levels of pro-inflammatory cytokines (e.g.,Interleukin-6).

  4. Changes in cellular components of the immune system between the HUC-MSC and placebo cohorts [ Time Frame: Baseline, month 3 and month 6 post infusion ]
    Flow cytometry will be used to identify the changes in numbers of lymphocyte subpopulations (e.g., B cells, T cells).

  5. Changes in Gut microbiota between the HUC-MSC and placebo cohorts [ Time Frame: Baseline, month 3 and month 6 post infusion ]
    The diversity and richness of gut microbiota at Phylum, Family and Species levels detected via next generation sequence



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects age ≥60 and ≤80 years at the time of signing the informed consent form.
  2. Must show signs of frailty apart from a concomitant condition as assessed by the investigator with a frailty score of 3 to 4 using the Fried Phenotype Scale.
  3. Must provide written informed consent.
  4. Subjects are expected to live more than 12 months.

Exclusion Criteria:

  1. Serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study
  2. Advanced liver or renal failure, class III/IV congestive heart failure, myocardial infarction, unstable angina, cardiac revascularization, or severe obstructive ventilator defect.
  3. Uncontrolled hypertension or hyperglycemia.
  4. Have known allergies to biological drugs or antibiotics.
  5. Expecting to receive organ transplantation.
  6. Have a clinical history of malignancy or active autoimmune diseases.
  7. Have a history of drug or alcohol abuse within the past 24 months.
  8. Be serum-positive for HIV, hepatitis BsAg or viremic hepatitis C.
  9. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.
  10. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04314011


Contacts
Layout table for location contacts
Contact: Hua Jiang, Ph.D 13311996820 Huajiang2013@tongji.edu.cn
Contact: Zhongming Liu, MD/Ph.D (+86)-21-38804518 liu.zhongmin@tongji.edu.cn

Locations
Layout table for location information
China
Shanghai East Hospital, Shanghai Tongji University
Shanghai, China, 200120
Contact: Hua Jiang, Ph.D    13311996820    huajiang2013@tongji.edu.cn   
Sponsors and Collaborators
Shanghai East Hospital
Xuanwu Hospital, Beijing
Investigators
Layout table for investigator information
Principal Investigator: Zhongming Liu, MD/Ph.D Shanghai East Hospital, Shanghai Tongji University
Layout table for additonal information
Responsible Party: Shanghai East Hospital
ClinicalTrials.gov Identifier: NCT04314011    
Other Study ID Numbers: EC.D (BG).020.02.0
First Posted: March 18, 2020    Key Record Dates
Last Update Posted: March 18, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Frailty
Pathologic Processes